Skip to main content

Table 1 Patients’ characteristics (data are shown as mean ± SD)

From: Quantitative imaging parameters to predict the local staging of prostate cancer in intermediate- to high-risk patients

  Total EPD +  EPD- p-value
Number of patients 73 31 42  
Age (years) 64.5 ± 6 (51–78) 66.3 ± 5.4 (53–76) 63.2 ± 6.2 (51–78) 0.026
PSA before PET/MRI (ng/ml) 14.4 ± 17.1 (1.2–104) 22 ± 20 (2.1–104) 10.3 ± 10.2 (1.22–55) 0.031
MRI (n)
 Internal–external 55–18 18–13 37–5  
 1.5–3.0 T 2–71 1–30 1–41  
 Endorectal coil–No coil 8–65 6–25 2–40  
Time between mpMRI and PET
 Days 64.6 ± 50.5 (0–175) 65.5 ± 48.1 (0–174) 63.9 ± 52.2 (0–175) 0.729
Clinical T stage (n)   0.052   
 T1 46/73 (63%) 16/31 (52%) 30/42 (71.5%)  
 T2 24/73 (32.5%) 12/31 (38.5%) 12/42 (28.5%)  
 T3 2/73 (3%) 2/31(6.5%) 0/42 (0%)  
 T4 1/73 (1.5%) 1/31 (3%) 0/42 (0%)  
ISUP biopsy grade n (%)   0.220   
 1 2/73 (3%) 0/31 (0%) 2/42 (5%)  
 2 10/73 (14%) 6/31 (19.5%) 4/42 (10%)  
 3 15/73 (20%) 4/31 (13%) 11/42 (26%)  
 4 30/73 (41%) 10/31 (32%) 20/42 (47%)  
 5 16/73 (22%) 11/31 (35.5%) 5/42 (12%)  
Time between PET and RPE
 Days 38.3 ± 31.2 (1–177) 36.2 ± 23.2 (3–93) 39.9 ± 35.9 (1–177) 0.969
ISUP RPE grade n (%)      < 0.001
 1 0/73 (0%) 0/31 (0%) 0/42 (0%)  
 2 9/73 (12.5%) 3/31 (10%) 6/42 (14%)  
 3 28/73 (38.5%) 5/31 (16%) 23/42 (55%)  
 4 17/73 (23%) 8/31 (26%) 9/42 (21%)  
 5 19/73 (26%) 15/31 (48%) 4/42 (10%)  
  1. Statistically significant p-values are marked by bold font
  2. EPD extraprostatic disease (on RPE specimen); SD standard deviation; mpMRI multiparametric magnetic resonance imaging; PET positron emission tomography/magnetic resonance imaging; PSA prostate-specific antigen; ISUP international society of urological pathology; and RPE radical prostatectomy